Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.

Also called NCT01522651

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 134 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01522651
  • EudraCT 2011-001134-42
Other papers using this trial's data
  • The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism Circulation. Arrhythmia and electrophysiology, 2015-10 DOI, PubMed 26226999

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Israel, Italy, Netherlands, Poland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01522651. Randomized; double masking; primary purpose treatment. Start 2012-01-24 (actual); primary completion 2014-03-10 (actual). Results posted on 2020-11-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Acronym
HARMONY
Intervention (Drug)
Ranolazine
Intervention (Drug)
Dronedarone
Intervention (Drug)
Ranolazine placebo
Intervention (Drug)
Dronedarone placebo
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct01522651
Content hash
f4188de39d36c09e4c8d07e7718c38864eaca7a070201088ecad5f2f39c7b499